Navigation Links
BioDelivery Sciences Announces Upcoming Presentations at Three Investor Conferences
Date:8/31/2011

RALEIGH, N.C., Aug. 31, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) today announced its participation at three upcoming investor conferences.  Dr. Mark A. Sirgo, President and Chief Executive Officer, will present at each conference where he will focus on BDSI's product pipeline, particularly BEMA Buprenorphine for the treatment of chronic pain, for which data from the pivotal Phase 3 efficacy study is anticipated in late September, and BEMA Buprenorphine/Naloxone for the treatment of opioid dependence.  

(Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO)


  • William Blair 2011 Life Sciences Conference
    Wednesday, September 7 at 12:10 PM Eastern Time (Panel)
    The Intercontinental New York Barclay, New York City

  • Stifel Nicolaus 2011 Healthcare Conference
    Thursday, September 8 at 2:05 PM Eastern Time
    Four Seasons Hotel, Boston

  • Rodman & Renshaw Annual Global Investment Conference
    Tuesday, September 13 at 10:00 AM Eastern Time
    The Waldorf-Astoria, New York City
  • Both the Stifel Nicolaus 2011 Healthcare Conference and the Rodman & Renshaw Annual Global Investment Conference presentations will be webcast live and can be accessed at www.bdsi.com.  For those who are not available to listen to the live broadcast, the presentations will be archived.

    About BioDelivery Sciences InternationalBioDelivery Sciences International (NASDAQ: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics.  BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and oncology supportive care.  BDSI's pain franchise currently consists of two products utilizing the patented BEMA technology.  ONSOLIS (fentanyl buccal soluble film) is approved in the U.S., Canada, and the E.U. (where it will be marketed as BREAKYL), for the management of breakthrough pain in opioid tolerant, adult patients with cancer.  The commercial rights are licensed to Meda for all territories worldwide except for Taiwan (licensed to TTY Biopharm) and South Korea (licensed to Kunwha Pharmaceutical Co.).  BDSI's second pain product, BEMA Buprenorphine, is being developed for the treatment of moderate to severe chronic pain and is in development in a high dose formulation for the treatment of opioid dependence.  Additional product candidates are being developed utilizing the BEMA technology for conditions such as nausea/vomiting (BEMA Granisetron).  BDSI's headquarters is located in Raleigh, North Carolina.  For more information, visit www.bdsi.com.

    BDSI® and BEMA® are registered trademarks of BioDelivery Sciences International, Inc.  ONSOLIS® is a registered trademark of Meda Pharmaceuticals, Inc.  BREAKYL is registered trademark of Meda Pharma GmbH & Co. KG.

    Cautionary Note on Forward-Looking StatementsThis press release, the presentation described herein and the statements of representatives and partners of BioDelivery Sciences International, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission.  Actual results (including, without limitation, the results of the clinical studies of BEMA Buprenorphine and BEMA Buprenorphine/Naloxone and regulatory review of such products) may differ significantly from those set forth or implied in the forward-looking statements. These forward-looking statements involve significant risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control).  The Company undertakes no obligation to publically update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.  Readers are cautioned that peak sales and market size estimates have been determined on the basis of market research and comparable product analysis, but no assurances can be given that such estimates are accurate or that such sales levels will be achieved, if at all.


    '/>"/>

    SOURCE BioDelivery Sciences International, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
    2. BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule
    3. BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting
    4. BioDelivery Sciences to Present at the 23rd Annual ROTH OC Growth Stock Conference
    5. BioDelivery Sciences Announces Completion of Recruitment in BEMA Buprenorphine Phase 3 Chronic Pain Study
    6. BioDelivery Sciences Provides Update on Status of Modified REMS Program for ONSOLIS
    7. BioDelivery Sciences to Present at the Jeffries Global Healthcare Conference
    8. BioDelivery Sciences Announces Commercial Launch of ONSOLIS in Canada
    9. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
    10. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
    11. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/2/2016)... - bioLytical lanza el INSTI HIV Self Test ... Continue Reading ... New: ... , , bioLytical Laboratories (la "Compañía"), ... está expandiendo el lanzamiento de su INSTI HIV Self Test  a África con ...
    (Date:12/2/2016)... North America held the largest share in the ... aged population and demand for remote monitoring ECG devices. On ... region is expected to witness the highest growth rate during ... Company (U.S.), Becton, Dickinson and Company (U.S.), Medtronic plc ( ... Netherlands ) and Mindray Medical International Limited ( ...
    (Date:12/2/2016)... Research and Markets has announced the addition of the ... 2022" report to their offering. ... , The global ultrasound device ... expected to grow at a CAGR of 5.5% during 2016-2022. Based on ... the forecast period, a CAGR of 8.8% in the global market. Among ...
    Breaking Medicine Technology:
    (Date:12/2/2016)... ... December 02, 2016 , ... The PAINWeekEnd ... Beach Resort and Spa in Honolulu, offering local frontline clinicians the opportunity to ... , The demand for supplemental training related to pain management has surged ...
    (Date:12/2/2016)... ... ... Yisrayl Hawkins, at The House of Yahweh in Abilene, Texas, has published ... Yisrayl says this generation, known as the Last Generation, started in 1934 A.Y. (After ... up exactly with Bible Prophecy – a protected way for those who will believe. ...
    (Date:12/2/2016)... ... December 02, 2016 , ... Today CloudMine, a ... applications, was named the best Sales Team of 2016 as part of the ... today by the Software & Information Industry Association (SIIA), the principal trade association ...
    (Date:11/30/2016)... (PRWEB) , ... November 30, 2016 , ... ... that they now offer a comprehensive in-house dental plan for all patients. Understanding ... developed a plan that gives patients a number of perks, including discounts on ...
    (Date:11/30/2016)... ... November 30, 2016 , ... Center ... has announced the opening of a new residential mental health treatment program in ... health issues such as severe anxiety, depression, bi-polar disorder, and other related issues. ...
    Breaking Medicine News(10 mins):